(MedPage Today) — MINNEAPOLIS — The small-molecule drug candidate danicamtiv showed promise for activating myosin in gene-related dilated cardiomyopathy (DCM), based on a small phase IIa study.
Suggesting boosted ventricular and atrial function…
Source link : https://www.medpagetoday.com/meetingcoverage/hfsa/117699
Author :
Publish date : 2025-09-29 18:46:00
Copyright for syndicated content belongs to the linked Source.
